3.79
0.05 (1.34%)
| Previous Close | 3.74 |
| Open | 3.76 |
| Volume | 191,057 |
| Avg. Volume (3M) | 350,158 |
| Market Cap | 180,429,968 |
| Price / Book | 1.18 |
| 52 Weeks Range | |
| Earnings Date | 6 Aug 2025 - 11 Aug 2025 |
| Operating Margin (TTM) | -11,193.25% |
| Diluted EPS (TTM) | -3.70 |
| Quarterly Revenue Growth (YOY) | -62.40% |
| Total Debt/Equity (MRQ) | 31.69% |
| Current Ratio (MRQ) | 1.69 |
| Operating Cash Flow (TTM) | -31.34 M |
| Levered Free Cash Flow (TTM) | -19.08 M |
| Return on Assets (TTM) | -48.28% |
| Return on Equity (TTM) | -92.35% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | SAB Biotherapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | -0.50 |
|
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 21.02% |
| % Held by Institutions | 23.99% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 15.00 (Guggenheim, 295.78%) | Buy |
| Median | 10.50 (177.05%) | |
| Low | 7.00 (UBS, 84.70%) | Buy |
| 7.00 (HC Wainwright & Co., 84.70%) | Buy | |
| Average | 10.75 (183.64%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 4.04 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Chardan Capital | 11 Mar 2026 | 14.00 (269.39%) | Buy | 4.10 |
| 18 Dec 2025 | 12.00 (216.62%) | Buy | 3.95 | |
| HC Wainwright & Co. | 10 Mar 2026 | 7.00 (84.70%) | Buy | 4.10 |
| UBS | 07 Jan 2026 | 7.00 (84.70%) | Buy | 3.97 |
| Guggenheim | 19 Dec 2025 | 15.00 (295.78%) | Buy | 3.99 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 04 Feb 2026 | Announcement | SAB BIO to Participate in Upcoming Investor Conferences |
| 07 Jan 2026 | Announcement | SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director |
| 06 Jan 2026 | Announcement | SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 18 Dec 2025 | Announcement | First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D |
| 17 Dec 2025 | Announcement | SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |